ICH E5(R1) - Ethnic Factors in the Acceptability of Foreign Clinical Data

What it says

E5(R1) describes a framework for evaluating the impact of ethnic factors on a medicine's effect, whether efficacy or safety, at a particular dosage and regimen, so that foreign clinical data can be accepted in a new region. It introduces the bridging data package and the bridging study as ways to extrapolate foreign data to a new population.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Differences in genetics, diet, medical practice and the disease itself can all affect how a drug works in a population.
• Drugs that are more sensitive to ethnic factors tend to need more local data.
• A bridging study can reduce the need to repeat a full development program in each region.

What inspectors look for

• Whether the sponsor assessed sensitivity of the drug to ethnic factors.
• Whether a bridging approach was justified.
• Whether local data support the extrapolation.

Related regulations